Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|June 30, 2017||4/7/2017||Interferon a2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis||Randomized Prospective Comparative Study of Interferon a2a and Cyclosporine in Patients With Refractory Behçet's Disease Uveitis||Behçet Disease;Uveitis||Drug: Interferon Alfa-2A;Drug: Cyclosporine Pill||Peking Union Medical College Hospital||NULL||Recruiting||18 Years||65 Years||All||36||Phase 3||China|
|2||JPRN-UMIN000025451||2017/04/01||28/12/2016||Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease||Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease - Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease||refractory uveitis of Behcet's disease||Patients with Behcet's disease who has received Infliximab intravenous infusion treatment at 8 week intervals over a long period (over 4 years) and calm eye inflammation, shall be discontinued from infliximab and be changed to cyclosporine A oral administration. For cases in which uveitis can not be suppressed and infliximab is reintroduced, if it is 20% or less, it shall be acceptable. Cyclosporine A is started orally at 5 mg / kg / day orally twice a day from 6 weeks after the final Infiximab administration, the maintenance dose is 3 to 5 mg / kg / day, and if the clinical findings are stabilized, Losing weight little by little is judged by the research doctor . The target trough value should be less than 150 ng / ml. The observation period of cyclosporine administration is one year.||Yokohama City University Hospital||NULL||Pending||20years-old||65years-old||Male and Female||5||Not selected||Japan|
|November 2004||9/9/2005||Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)||Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet's Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB)||Behcet's Disease;Panuveitis;Posterior Uveitis;Retinal Vasculitis||Drug: Cyclosporin A;Drug: Interferon-alpha2a||University Hospital Tuebingen||NULL||Completed||18 Years||75 Years||All||37||Phase 3||Germany|